{"id":"NCT02207816","sponsor":"GlaxoSmithKline","briefTitle":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","officialTitle":"Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-18","primaryCompletion":"2017-01-31","completion":"2017-01-31","firstPosted":"2014-08-04","resultsPosted":"2019-08-15","lastUpdate":"2019-11-25"},"enrollment":3084,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Malaria"],"interventions":[{"type":"PROCEDURE","name":"Blood sampling","otherNames":[]},{"type":"BIOLOGICAL","name":"Malaria Vaccine 257049 (MALARIA-055 PRI)","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)","otherNames":["Menjugate"]},{"type":"BIOLOGICAL","name":"Cell-culture rabies vaccine (MALARIA-055 PRI)","otherNames":["VeroRab"]},{"type":"BIOLOGICAL","name":"TritanrixHepB/Hib (MALARIA-055 PRI)","otherNames":[]},{"type":"BIOLOGICAL","name":"Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)","otherNames":[]}],"arms":[{"label":"GSK257049 Group","type":"EXPERIMENTAL"},{"label":"GSK257049 Comparator Group","type":"ACTIVE_COMPARATOR"},{"label":"VeroRab/Menjugate Comparator Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following a primary vaccination series (NCT00866619). No new subjects will be enrolled in this extension study.","primaryOutcome":{"measure":"Incidence of Severe Malaria Meeting Case Definition 1","timeFrame":"From Year 0 to Year 3 (Starting January 2014 and ending December 2016)","effectByArm":[{"arm":"GSK257049 [5-17M] Group","deltaMin":0.001,"sd":null},{"arm":"GSK257049 Comparator [5-17M] Group","deltaMin":0.002,"sd":null},{"arm":"VeroRab Comparator [5-17M] Group","deltaMin":0.002,"sd":null},{"arm":"GSK257049 [6-12W] Group","deltaMin":0.004,"sd":null},{"arm":"GSK257049 Comparator [6-12W] Group","deltaMin":0.003,"sd":null},{"arm":"Menjugate Comparator [6-12W] Group","deltaMin":0.005,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.2235"},{"comp":"OG001 vs OG002","p":"0.8972"},{"comp":"OG003 vs OG005","p":"0.5333"},{"comp":"OG004 vs OG005","p":"0.3523"}]},"eligibility":{"minAge":"42 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":3,"countries":["Burkina Faso","Kenya","Tanzania"]},"refs":{"pmids":["31300331"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":1051},"commonTop":[]}}